What You Should Know:
- Pfizer Inc. has announced a historic agreement with the Trump Administration that is designed to ensure U.S. patients pay lower prices for their prescription medicines while strengthening America’s role as the global leader in biopharmaceutical innovation.
- The voluntary agreement, made in response to a presidential letter, aims to implement measures that ensure Americans receive drug prices comparable to those available in other developed
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Sanofi Commits Additional $625M to Sanofi Ventures to Fuel Biotech and Digital Health Innovation
What You Should Know:
- Sanofi Ventures has announced a significant $625M multi-year capital commitment from Sanofi, substantially increasing its total assets under management (AUM) to over $1.4B.
- The new capital injection into the evergreen venture fund reinforces Sanofi's strong belief that important medical breakthroughs often begin in early-stage companies.
Fueling Strategic Growth in Key Therapeutic Areas
The new funding commitment builds on more than a decade of
Read More
Beyond the “Batch of One”: How Flexible Manufacturing is Revolutionizing Biopharma
Biopharmaceutical companies today are facing a very different manufacturing challenge than they were a decade ago. Traditional production models were built to make large volumes of a small number of products. But with the rise of targeted therapies, faster development cycles, and increasing demand for personalized medicine, that one-size-fits-all approach no longer works.
Now, the industry is under pressure to support smaller batches, more complex processes, and tighter timelines—without
Read More
Ryght AI’s Clinical Research Platform Now Available on Microsoft Azure Marketplace
What You Should Know:
- Ryght AI today announced that its innovative clinical research platform is now available on Microsoft Azure Marketplace, providing sponsors and contract research organizations (CROs) with streamlined access to AI-powered site selection and feasibility workflows.
- This availability enables healthcare organizations to leverage their existing Microsoft Azure cloud commitments while accelerating clinical trial processes through advanced generative and agentic AI
Read More
Pfizer Acquires Metsera for $4.9B, Expanding into Obesity and Cardiometabolic Market
What You Should Know:
- Pfizer Inc. and Metsera, Inc. have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company focused on developing medicines for obesity and cardiometabolic diseases for $4.9B.
- The acquisition is a strategic move for Pfizer, allowing it to enter a significant and growing therapeutic area. The Boards of Directors of both companies have unanimously approved the transaction.
Financial Terms
Read More
Lunit and Agilent Partner to Develop AI-Powered Companion Diagnostics for Cancer
What You Should Know:
- Lunit, a provider of AI for cancer diagnostics, and Agilent Technologies Inc., a global leader in life sciences, have announced a nonexclusive collaboration to develop AI-based companion diagnostic solutions.
- The strategic partnership will combine Lunit's AI technology with Agilent’s expertise in tissue-based companion diagnostics. The goal is to create advanced solutions that meet the demands of novel and complex biomarker assays in drug
Read More
Bar-Ilan University and Sheba Medical Center to Launch $120M Biotech Research Institute
What You Should Know:
- Bar-Ilan University and Sheba Medical Center have announced the establishment of a joint research institute.
- The $120M institute will serve as a bridge between academia, healthcare, and industry to accelerate the translation of laboratory discoveries into clinical treatments. It will be located within Sheba’s new Health Tech Valley (HTV) in Ramat Gan, which is owned by Migdal Insurance and Financial Holdings.
Biotech Institue Focus Areas
The new
Read More
Why AI Isn’t Curing Disease, Yet: Crossing Pharma’s Valley of Death with Physical Intelligence
We were told AI would cure disease in years. That’s a fallacy.
Today, over 90% of clinical drug candidates still fail. It costs more than $2 billion and over a decade to bring a single drug to market. And now the industry faces a brutal paradox, which is the promise of exponential progress stuck inside a system governed by diminishing returns.
This is pharma’s version of Eroom’s Law, i.e. the inverse of Moore’s Law, where the return on drug development declines as science
Read More
Causaly Introduces First Agentic AI Platform Built for Life Sciences Research and Development
What You Should Know:
- Causaly today announced Causaly Agentic Research, an agentic AI platform designed specifically for life sciences research and development.
- Built to deliver transparency and scientific rigor, the platform’s specialized AI agents access, analyze, and synthesize internal and external biomedical knowledge and competitive intelligence—so teams can automate complex workflows, uncover novel insights, and move from hypothesis to decision faster and with greater
Read More
Inato Unveils AI Capabilities to Transform Clinical Trial Site Selection
What You Should Know:
- Today, Inato unveiled new AI capabilities to enhance and accelerate site selection. Sponsors can now use Inato’s platform to create and execute data-driven site selection scenarios based on real-time interest and verified data from over 5,500 sites quickly and easily.
- The new capabilities fill an acute gap for sponsor decision-makers, arming them with the insights they need to quickly and confidently choose the right mix of sites for each trial.
Inato Unveils
Read More
